Catalyze Your Research with the Right Target Profile
Breakthrough discoveries start with the right model selection. Our prostate cancer platform is fully characterized for key surface antigens to give you more reliable and predictive results for targeted therapies.
Validated H-scores for PSMA and STEAP1 allow for precise evaluation of ADs and radioligands.
Unique "Double Positive" PDX models that express both FOLH1 and STEAP1, ideal for testing bispecific antibodies and combination therapies.
Models derived from distinct metastatic sites, including bone, brain, and lymph nodes, to study CRPC mechanisms.
A full spectrum of AR status, ranging from sensitive to splice variant AR-V7 expressers and completely androgen-independent phenotypes.
Paired organoid and PDX models derived from the same patient tumor enable seamless translation from in vitro screening to in vivo validation
Representation of critical genetic drivers and rare subtypes, including TMPRSS2-ERG fusion positive and neuroendocrine prostate cancer.
Comprehensive Prostate Cancer Models & Translational Insights
Advancing prostate cancer drug development requires clinically relevant models and deep translational understanding. Our prostate cancer factsheet highlights a broad portfolio of patient‑derived xenografts (PDX), matched patient‑derived organoids, syngeneic and GEMM models that capture disease heterogeneity across hormone‑responsive, CRPC, and mCRPC settings. Gain insight into model selection, treatment history, and biomarker characterization to support informed decision‑making.
From In Vitro Screening to In Vivo Validation
Support your ADC efficacy studies with our diverse portfolio of translational models. We offer patient-derived xenografts (PDX), syngeneic, and humanized models to simulate real-world tumor biology. Our extensive cancer model database allows researchers to identify the most relevant tumor models for their studies. Additionally, we provide pharmacokinetics (PK) assessments to quantify intact ADCs, antibodies, and small-molecule payloads.
Matched PDX-organoid pairs enable rapid compound screening in 384-well format with validated SOC responses (docetaxel, enzalutamide, abiraterone, cabazitaxel) and seamless translation to in vivo validation.
Nine patient-derived models covering HR, CRPC, and mCRPC disease states with extensive treatment histories. Models feature quantified PSMA expression (RNA-seq + IHC H-scores), AR/AR-V7 profiling, and validated resistance phenotypes.
.webp)
Test compounds on fresh prostate tumor samples. Preserve native tumor microenvironment and immune interactions with short turnarounds for rapid clinical trial stratification and biomarker discovery.
Access a comprehensive panel of well-characterized prostate cancer Cell Line Derived Xenograft (CDX) models, including LNCaP, 22RV-1, and PC-3. Fully profiled for AR status, AR-V7 variants, and PSMA expression to provide reliable, reproducible in vivo benchmarking for your targeted therapies and standard-of-care comparisons.
Prostate Cancer Model Capabilities
| Capability | PDX | Organoids | Syngeneic | EVPT |
|---|---|---|---|---|
| Retained treatment history |  |
|
- | |
| PSMA / AR characterization | |
|
- | |
| High‑throughput screening | - | |
- | |
| Immunocompetent setting | - | - | |
|
| In vivo efficacy testing | |
- | |
- |
.webp)
